July 2019 Volume 15, Issue 7
Volume 15, Issue 7 | July 2019
July 2019
In this Issue
Research & Development
Meet the Mini-Brain
AxoSim licenses revolutionary Mini-Brain technology from Johns HopkinsAmicus-Penn collaboration gains new life
Partners have expanded their agreement to include new indications and new research programsA banner day for modeling
Q2 saw encouraging advances in disease modeling optionsCollaboration center
Platform will help to characterize biotherapeutic productsA need for diversity
Study finds that over 75 percent of genomic data is of European originDiscovery
Working to ‘develop tomorrow’s drugs’
GSK, University of California to establish new lab for genetic and CRISPR researchGilead, Goldfinch take aim at kidney disease
All told, the total deal value could reach over $2B if all milestones are metBig agreements for Atomwise
Atomwise announces deals with Eli Lilly and EnamineA better picture of how antibiotics kill
Machine learning reveals metabolic pathways disrupted by the drugsAccelerating antibiotics
Polyphor and the University of Zurich examine new class of drugs inhibiting the LPS transport pathwayClinical Trials
A new network
National Kidney Foundation introduces its plan for an expansive kidney disease registryIf at first you don't succeed...
Despite setback with IFX-1, InflaRx continues testingImago unveils IMG-7289
Safety and efficacy data informs expansion of study into Phase 2bDesign in the cloud
Exploristics announces launch of KerusCloud 2.0A faster track for flu vaccine
Novavax confirms accelerated approval pathway available for licensure of NanoFluSpecial Reports
Special Report on Drug Screening: Phenotypic finery
Microscopy meets the molecular in the search for phenotypic impacts in drug screeningFeature
Focus Feature on Cancer Research News: Hitting the target
It’s never just been about killing or removing tumors; it’s about aiming at them accuratelyCommentary
Guest Commentary: ACT clinical trials--The long road
As excitement and investment related to adoptive cell transfer products increases, there are concerns and issues that need to be addressed in terms of long-term follow-up trialsOut of order: Inverted focus?
Our microbiomes might adversely influence some therapeutics that we take, but does that mean that we should be altering the microbiome to compensate?Editor's Focus
Editor’s focus: Off-target effect from inactives?
More information about adverse effects of so-called 'inactive' ingredients could be useful, but it also could just be a ton more information that we can't do much with once we have itPreclinical
Stem-ulating research
Two branches of stem cell research discover the impact on both diabetes and cardiac damagePotential to treat Pompe disease
Findings validate gene therapy approachImmunotherapies vs. infections
Breakthrough research identifies a potential vaccine against deadly fungusThe rodents shall remain
Rats and mice expected to continue as most lucrative species for animal modelsBusiness & Government Policy
AbbVie makes $63B play for Allergan
Proposed acquisition is said to be a ‘tranformative’ move for both companiesOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsAdvancing biologics
FDA takes new step to help advance the transition of certain biological productsNew mass spec for Thermo
Thermo Fisher Scientific acquires Slovakian mass spec software firm HighChemPatent Docs: BIO International Convention wrap-up
Kevin Noonan, a partner with the law firm McDonnell Boehnen Hulbert & Berghoff LLP and founding author of the Patent Docs weblog, recaps the highlights of the latest annual BIO meetingDiagnostics
Double duty for ingestible technology
Micro-bio-electronic device might be able to diagnose and treat GI problemsA stool test for cirrhosis
UC San Diego researchers analyze stool microbes to diagnose liver diseaseADDF commits $50M to early AD detection
Alzheimer’s Drug Discovery Foundation aims to fast-track digital tools for the disease‘Liquid’ assets
A look at a recent FDA decision and analyst forecasts in the field of liquid biopsyContract Services
Charles River cultivates change
Charles River constructs new collaborative science partnershipsAldevron adds space
Biologics manufacturer expands and names new business heads
